VERO Venus Concept

Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024

Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024

TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024.

Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2024, to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13745887. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.

For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13745887. The webcast will be archived at ir.venusconcept.com.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors, including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.



Investor Relations Contact:

ICR Westwicke on behalf of Venus Concept

Mike Piccinino, CFA

 
EN
15/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Announces Loan Purchase and Completion of First Phase of...

Venus Concept Announces Loan Purchase and Completion of First Phase of Refinancing MSLP Loan Purchase and Short-term Bridge Financing of Up To $5.0 million By Madryn Asset Management TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that on April 23, 2024, its existing Main Street Lending Program Loan (“MSLP Loan”) was purchased by affiliates of Madryn Asset Management, LP (“Madryn”) for an undisclosed amount from the City National Bank of Florida (“CNB”) with th...

 PRESS RELEASE

Venus Concept to Release First Quarter of Fiscal Year 2024 Financial R...

Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024 TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2024, to discuss the results of the quarter with a question and answer session. Those who would like to participate may dia...

 PRESS RELEASE

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MA...

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions. The Venus Bliss MAX offers three advanced technologies in one platform: diode las...

 PRESS RELEASE

Venus Concept Announces Australian Regulatory Approval for Venus Versa...

Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has Therapeutic Goods Administration (TGA) clearance in Australia to market the Venus Versa Pro system. The Venus Versa Pro combines the applicator of the Venus Viva MD with the Venus Versa system which are both approved in Australia and registered in Australian Register of Therapeutic Goods (ARTG). The Venus Versa Pro offers a total...

 PRESS RELEASE

Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ...

Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior year Cash used in operations for fiscal year 2023 of $12.9 million...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch